Effect of Termisartan or Losartan in Hypertensive Diabetic Patients with Macroalbumiuria

Effect of Termisartan or Losartan in Hypertensive Diabetic Patients with Macroalbumiuria - MOLOYAMA Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000797

Enrollment

100

Registered

2007-08-10

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Diabetic Nephropathy Patients with Macroalbumiuria

Interventions

Continue oral administration of Losartan (25-100mg/day) Switch to oral administration of Telmisartan (20-80mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diabetic nephropathy patients with macroalbumiuria (Urinary Protein >1+) 2)Hypertensive patients taking Losartan

Exclusion criteria

Exclusion criteria: 1) Non diabetic nephropathy (e.g. IgA nephropathy, Nephrosclerosis, etc) 2) Patients who are taking ACRs and/or ARBs other than Losartan 3) Serum creatinine > 3.0mg/dl 4) Severe hypertension (Diastolic blood pressure > 120mmHg) 5) Patients who are inadequate to entry this study by physicians in charge

Design outcomes

Primary

Measure	Time frame
Changes of urinary excretion of protein after 12 weeks of treatment	—

Secondary

Measure	Time frame
1) Changes in office blood pressure after 12 weeks treatment 2) Changes in serum creatinine,high molecular adeponectine, potassium, total cholestero, HDL-cholesterol, triglyceride, blood glucose, IRI, HbA1c, HOMA-IR after 12 weeks of treatment	—

Countries

Japan

Contacts

Public ContactHidetomo Nakamoto

Saitama Medical University Department of General Medicine

nakamo_h@saitama-med.ac.jp049-276-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026